This Site Is Intended for US Healthcare Professionals Only
3 INDICATIONS VOQUEZNA® (vonoprazan) is indicated for the healing of all grades of Erosive Esophagitis in adults Read More

VOQUEZNA demonstrated sustained
healing rates in all grades of Erosive
GERD1,2

Met the primary endpoint for maintenance of healing: noninferiority vs lansoprazole

PRIMARY NONINFERIORITY ENDPOINT: MAINTENANCE OF HEALING RATES THROUGH WEEK 24 IN ALL GRADES1,2
Bar graph shows that for the primary noninferiority endpoint of maintenance of healing rates through Week 24 in all grades, 79% of patients on VOQUEZNA achieved maintenance of healing vs 72% on lansoprazole
79% of VOQUEZNA patients achieved sustained healing
Superior rates of sustained healing in all grades with VOQUEZNA vs a PPI
Achieved superior sustained healing rates in Grades C/D patients1,2
SECONDARY SUPERIORITY ENDPOINT: MAINTENANCE OF HEALING RATES THROUGH WEEK 24 FOR GRADES C/D1,2,*
Bar graph shows that for the secondary superiority endpoint of maintenance of healing through Week 24 in LA grades C and D, 75% of patients on VOQUEZNA achieved maintenance of healing vs 61% of patients on lansoprazole
Superior sustained healing rates with VOQUEZNA vs a PPI in patients with moderate-to-severe disease

*Severity of the disease was classified based on the LA Classification Grading System (Grades A through D), with mild Erosive Esophagitis being Grades A or B and severe Erosive Esophagitis being Grades C or D.1,2

VOQUEZNA provided 4 out of 5 complete heartburn-free days1
SECONDARY NONINFERIORITY ENDPOINT: PERCENTAGE (%) OF 24‑HOUR HEARTBURN‑FREE DAYS THROUGH WEEK 241
Secondary non inferiority endpoint: percentage of 24-hour heartburn-free days through week 24
Approved for relief of heartburn related to Erosive GERD11
SEE SAFETY DATASEE HEALING RESULTS
SEE
NON-EROSIVE
GERD DATA